Penn Center for Innovation

Linnaeus Therapeutics announces first patient dosed in its clinical trial of LNS8801 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced cancer

Posted on October 14, 2020 — Jessica Jones Gupta

Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that it has dosed the first patient in its phase 1/2 adaptive-design clinical trial of its lead-product-candidate, LNS8801, in combination with KEYTRUDA ® (pembrolizumab) in patients who had previous clinical benefit from immune checkpoint inhibitors and then subsequently progressed. This marks the first time any company has dosed a patient in a clinical trial specifically targeting the G protein-coupled estrogen receptor (GPER) in combination with pembrolizumab. The initiation of the study follows the successful identification of the recommended phase 2 dose (RP2D) in the Company’s ongoing study of LNS8801.

Read the Linneaus Press Release

Category: external, news